Prestige Over Progress: How Femtech Prioritises Headlines Over Women’s Health
Publishing in high-profile journals or partnering with prestigious institutions can boost credibility and attract investors, even if the research has little bearing on meaningful health outcomes.
Why do period apps choose Technology Institutes over hospitals, press releases over patients?
The incentives reveal the dark side of femtech. While headlines get clicks and prestige earns funding, women’s health often takes a back seat.
Study Incentives
Femtech companies frequently fund studies designed for visibility rather than clinical impact. Publishing in high-profile journals or partnering with prestigious institutions can boost credibility and attract investors, even if the research has little bearing on meaningful health outcomes.
These “easy wins” often explore correlations that are simple to measure, like environmental factors or app engagement patterns, rather than tackling complex health problems that truly affect women.
Complexity vs. Risk
Clinical studies that could directly improve patient care are slow, costly, and heavily regulated. They require ethical oversight, longitudinal tracking, and clinical validation. From an app company’s perspective, these hurdles reduce speed to market, increase liability, and offer fewer headlines for press coverage.
The result? Women’s health issues that are complicated, under-researched, or high-risk, like endometriosis, PCOS, or menstrual disorders, remain underexplored.
Publishing in high-profile journals or partnering with prestigious institutions can boost credibility and attract investors, even if the research has little bearing on meaningful health outcomes.
Industry Implications
This incentive structure shapes the femtech industry. Prestige and marketing visibility often outweigh patient outcomes in decision-making. Apps with glossy dashboards and “Technology-backed research” appear innovative, even if they provide minimal clinical benefit.
Investors and media coverage reward prestige, creating a cycle where shiny data correlations are celebrated while meaningful health solutions are delayed or ignored.
Emotional Angle
For women, this lag is personal. Millions track symptoms daily, hoping for actionable guidance. Instead, they often receive insights that are interesting but clinically inconsequential. The emotional cost: frustration, anxiety, and delayed care. Women’s pain is real.
